the vaccines may not have included serogroup B – the most common serogroup associated with IMD in Canada.
TRUMENBA targets a protein found in over 95% of bacteria that cause meningitis B. It works by helping the body make antibodies (the body’s natural defenses), which can help protect individuals against this disease. These antibodies kill the bacteria that cause meningitis B.
If a vaccinated person comes into contact with the bacteria that cause this disease, their body is usually ready to destroy them.
Your healthcare professional will inject TRUMENBA into the upper arm muscle as a single injection of 0.5 mL, on two or three separate occasions.
NACI recommends that TRUMENBA may be considered as an option for individuals 10–25 years of age who are not at higher risk of meningococcal disease than the general population, in a 2-dose schedule (0 and 6 months), to reduce the risk of invasive serogroup B meningococcal disease.
NACI: National Advisory Committee on Immunization.
